Semanteon Capital Management LP Acquires New Shares in Blueprint Medicines Co. (NASDAQ:BPMC)

Semanteon Capital Management LP acquired a new stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 12,758 shares of the biotechnology company’s stock, valued at approximately $1,177,000.

Other institutional investors also recently modified their holdings of the company. American Century Companies Inc. boosted its position in shares of Blueprint Medicines by 5.2% during the third quarter. American Century Companies Inc. now owns 670,972 shares of the biotechnology company’s stock valued at $33,696,000 after buying an additional 33,243 shares during the last quarter. Diversified Trust Co boosted its position in Blueprint Medicines by 2.9% in the third quarter. Diversified Trust Co now owns 11,219 shares of the biotechnology company’s stock worth $563,000 after purchasing an additional 318 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in Blueprint Medicines by 95.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,550 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 757 shares during the last quarter. Rafferty Asset Management LLC boosted its position in Blueprint Medicines by 17.4% in the third quarter. Rafferty Asset Management LLC now owns 166,690 shares of the biotechnology company’s stock worth $8,371,000 after purchasing an additional 24,693 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in Blueprint Medicines by 0.6% in the third quarter. Vanguard Group Inc. now owns 5,967,143 shares of the biotechnology company’s stock worth $299,670,000 after purchasing an additional 37,716 shares during the last quarter.

Insiders Place Their Bets

In other Blueprint Medicines news, Director Jeffrey W. Albers sold 25,073 shares of Blueprint Medicines stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $87.28, for a total value of $2,188,371.44. Following the sale, the director now owns 176,050 shares of the company’s stock, valued at approximately $15,365,644. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, CFO Michael Landsittel sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, March 28th. The stock was sold at an average price of $95.00, for a total transaction of $475,000.00. Following the transaction, the chief financial officer now owns 47,286 shares of the company’s stock, valued at approximately $4,492,170. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Jeffrey W. Albers sold 25,073 shares of the stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $87.28, for a total value of $2,188,371.44. Following the sale, the director now owns 176,050 shares in the company, valued at approximately $15,365,644. The disclosure for this sale can be found here. Insiders have sold a total of 92,289 shares of company stock valued at $8,314,163 in the last quarter. 3.88% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several brokerages have issued reports on BPMC. Stifel Nicolaus raised their target price on Blueprint Medicines from $95.00 to $97.00 and gave the stock a “buy” rating in a research report on Tuesday, January 9th. Barclays raised their target price on Blueprint Medicines from $58.00 to $70.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 13th. Needham & Company LLC reissued a “buy” rating and issued a $97.00 target price on shares of Blueprint Medicines in a research report on Monday, February 26th. JMP Securities reaffirmed a “market outperform” rating and set a $114.00 price objective on shares of Blueprint Medicines in a research report on Wednesday, April 10th. Finally, Citigroup lifted their price objective on Blueprint Medicines from $54.00 to $65.00 and gave the company a “sell” rating in a research report on Friday, February 16th. Four analysts have rated the stock with a sell rating, two have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Blueprint Medicines currently has a consensus rating of “Hold” and a consensus target price of $85.43.

Blueprint Medicines Price Performance

BPMC traded down $1.53 on Thursday, hitting $90.73. 755,177 shares of the company’s stock traded hands, compared to its average volume of 764,408. The company’s 50 day simple moving average is $90.73 and its 200-day simple moving average is $78.51. The firm has a market cap of $5.55 billion, a price-to-earnings ratio of -10.85 and a beta of 0.63. Blueprint Medicines Co. has a one year low of $43.89 and a one year high of $101.00. The company has a current ratio of 3.76, a quick ratio of 3.66 and a debt-to-equity ratio of 1.60.

Blueprint Medicines (NASDAQ:BPMC) last issued its earnings results on Thursday, February 15th. The biotechnology company reported ($1.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.04) by $0.22. The company had revenue of $71.96 million for the quarter, compared to the consensus estimate of $67.34 million. Blueprint Medicines had a negative return on equity of 191.56% and a negative net margin of 203.30%. The firm’s quarterly revenue was up 85.5% on a year-over-year basis. During the same quarter last year, the company earned ($2.65) EPS. As a group, research analysts anticipate that Blueprint Medicines Co. will post -5.41 EPS for the current year.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.